CMRX Overview
Upcoming Projects (CMRX)
-
Don’t see a project related to the company you care about? Create your own!
Executed Projects (CMRX)
-
Discussing Chimerix' ONC-201 in recurrent H3 K27M-mutant glioma with the Phase 3 ACTION study underway
Ticker: CMRX
Executed On: Mar 03, 2023 at 03:00 PM EST -
Discussing Day One Bio’s Tovorafenib (DAY101) in Recurrent or Progressive Pediatric Low-Grade Glioma following Pivotal Phase 2 data results
Tickers: DAWN, CMRX
Executed On: Jan 25, 2023 at 03:00 PM EST -
Monkeypox Expert Survey: Concerns and Treatment Needs
Tickers: SIGA, CMRX, EBS, BVNRY
Executed On: Aug 04, 2022 at 12:27 PM EDT -
Another Look: Digging into Chimerix (CMRX) ONC-201 in recurrent H3 K27M-mutant glioma
Ticker: CMRX
Executed On: Jan 05, 2022 at 03:00 PM EST
Expired Projects (CMRX)
-
Discussing Chimerix’ ONC206 Candidate in Recurrent Diffuse Midline Gliomas, and Other Recurrent Malignant Brain Tumors
Ticker: CMRX
Execute By: Oct 31, 2021
Upcoming & Overdue Catalysts (CMRX)
-
Don’t see a catalyst related to the company you care about? Create your own!
Occurred Catalysts (CMRX)
-
PDUFA set to July 7, 2021 for Chimerix's(CMRX) Brincidofovir as a Medical Countermeasure for Smallpox
Ticker: CMRX
Occurred on: Jun 04, 2021 -
A full analysis of the SUPPRESS trial results is ongoing and will be presented at the BMT Tandem Meetings in Honolulu, Hawaii.
Ticker: CMRX
Occurred on: Feb 20, 2016
Strategic Initiatives (CMRX)
-
Don’t see a strategic initiative related to the company you care about? Create your own!
